Tag Archives: STEAP-1

Thoughts on AstraZeneca’s Cell Therapy Pipeline

On Monday, January 16, AstraZeneca (AZ) announced (press release) the completion of Neogene Therapeutics’ acquisition for developing TCR-T therapies in solid tumors. Moreover, during JPM 2023, AZ introduced (presentation) AZD5851 (GPC3 armored CAR-T), its first official cell therapy program. Below, Celltelligence provides insights on AstraZeneca’s increasing interest in cell therapies, while discussing the potential of its innovative cell therapy pipeline.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.